Infant Bacterial Correlations
| IBT-B Stock | SEK 50.20 3.20 5.99% |
The current 90-days correlation between Infant Bacterial and Cantargia AB is 0.06 (i.e., Significant diversification). The correlation of Infant Bacterial is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Infant Bacterial Correlation With Market
Significant diversification
The correlation between Infant Bacterial Therapeutics and DJI is 0.01 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Infant Bacterial Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Infant |
The ability to find closely correlated positions to Infant Bacterial could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Infant Bacterial when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Infant Bacterial - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Infant Bacterial Therapeutics to buy it.
Moving together with Infant Stock
Moving against Infant Stock
| 0.75 | HEART | Real Heart Split | PairCorr |
| 0.64 | XINT | Xintela AB | PairCorr |
| 0.6 | VITR | Vitrolife AB | PairCorr |
| 0.59 | CMH | Chordate Medical Holding | PairCorr |
| 0.58 | CAMX | Camurus AB | PairCorr |
| 0.56 | CYXO | Cyxone AB | PairCorr |
| 0.55 | HNSA | Hansa Biopharma AB | PairCorr |
| 0.34 | NANOFS | Nanoform Finland Plc | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Infant Stock performing well and Infant Bacterial Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Infant Bacterial's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BIOG-B | 1.06 | (0.08) | 0.00 | 0.84 | 0.00 | 2.46 | 7.49 | |||
| CANTA | 3.01 | (0.55) | 0.00 | 0.23 | 0.00 | 4.47 | 47.04 | |||
| XSPRAY | 2.38 | (0.06) | 0.00 | 0.25 | 0.00 | 6.25 | 25.50 | |||
| IMMNOV | 5.50 | 0.13 | 0.04 | 0.17 | 7.37 | 7.81 | 80.75 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Infant Bacterial without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
| All Next | Launch Module |
Infant Bacterial Corporate Management
Elected by the shareholders, the Infant Bacterial's board of directors comprises two types of representatives: Infant Bacterial inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Infant. The board's role is to monitor Infant Bacterial's management team and ensure that shareholders' interests are well served. Infant Bacterial's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Infant Bacterial's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anders Kronstrm | Chief Officer | Profile | |
| Maria Ekdahl | Chief Officer | Profile | |
| Robert Molander | Chief Officer | Profile | |
| Pr MD | Chief Officer | Profile | |
| Staffan Stromberg | Chief Officer | Profile |